odanacatib

Known as: (2S)-N-(1-Cyanocyclopropyl)-4-fluoro-4-methyl-2-(((1S)-2,2,2-trifluoro-1-(4'-(methylsulfonyl)(1,1'-biphenyl)-4-yl)ethyl)amino)pentanamide 
An inhibitor of cathepsin K with potential anti-osteoporotic activity. Odanacatib selectively binds to and inhibits the activity of cathepsin K… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2008-2018
010203020082018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
INTRODUCTION The market of antiosteoporosis drugs has been declining in recent years, possibly in part due to the publicity… (More)
Is this relevant?
2014
2014
Odanacatib is a cathepsin K inhibitor investigated for the treatment of postmenopausal osteoporosis. Phase 2 data indicate that… (More)
  • figure 1
  • table 2
  • table 3
Is this relevant?
2013
2013
CONTEXT Odanacatib, a cathepsin K inhibitor, increases spine and hip areal bone mineral density (BMD) in postmenopausal women… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Odanacatib (ODN) is a selective and reversible inhibitor of cathepsin K (CatK). Previously, ODN was shown to increase bone… (More)
Is this relevant?
Highly Cited
2011
Highly Cited
2011
The selective cathepsin K inhibitor odanacatib (ODN) progressively increased bone mineral density (BMD) and decreased bone… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2011
2011
Odanacatib (ODN) is a selective, potent and reversible inhibitor of cathepsin K (CatK) that inhibits bone loss in postmenopausal… (More)
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Cathepsin K, a cysteine protease expressed in osteoclasts, degrades type 1 collagen. Odanacatib selectively and reversibly… (More)
Is this relevant?
2010
2010
BACKGROUND Metastatic bone disease (MBD) is a frequent complication in patients with breast cancer and is associated with… (More)
Is this relevant?
2009
2009
The successful formulation of itraconazole and odanacatib into nanoparticle form with diameters of 145 and 350 nm, respectively… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 5
  • table 1
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Odanacatib is a potent, selective, and neutral cathepsin K inhibitor which was developed to address the metabolic liabilities of… (More)
Is this relevant?